ENTITY

Mirxes (2629 HK)

32
Analysis
Health Care • Singapore
Mirxes is a Singapore-headquartered micro ribonucleic acid (miRNA) technology company that develops diagnostic solutions for the early detection of diseases, including cancer, cardiovascular, metabolic, and infectious diseases. Its key products include GASTROClear, a blood-based test for gastric cancer screening, and LUNGClear for lung cancer screening, along with Fortitude COVID-19 RT-qPCR test kits. The company was founded in 2014.
more
•29 Nov 2025 11:05

Hong Kong: IPO SPOTLIGHT - OVERVIEW 2025

Hong Kong is the top global destination for IPOs in 2025, with over HK $280 billion raised so far.  Large scale A+H dual listings have surged this...

Logo
961 Views
Share
•21 Sep 2025 10:05

HK Connect Flows Weekly (Sep 19th): Alibaba, Beigene, China Pacific Insurance

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Alibaba, Beigene, China Pacific Insurance, Duality...

Logo
706 Views
Share
bullish•CaoCao
•25 Aug 2025 05:50

HSCI Index Rebalance: 24 Adds, 22 Deletes, Changes to Southbound Stock Connect & BIG Outperformance

There are 24 adds and 22 deletes for the HSCI in Sep. 20 stocks could be added to Stock Connect and 19 removed. The Connect adds have outperformed...

Logo
849 Views
Share
bullish•IFBH
•25 Jul 2025 06:33

HSCI Index Rebalance Preview and Stock Connect (Sep 2025): Plenty of Recent IPOs Could Be Added

The forecast adds to the index and Stock Connect are up 9.7% on average this month while the forecast deletes from the index and Stock Connect are...

Logo
1.7k Views
Share
•15 Jul 2025 07:30

CICC (3908 HK): It Is the Best of the Time

​CICC is alerting a strong 1H25 profit growth, leading in the HK IPO market with a promising H-share IPO pipeline of A-share companies. The market...

Logo
548 Views
Share
x